There are currently 50 active clinical trials seeking participants for Migraine research studies. The states with the highest number of trials for Migraine participants are Florida, California, Texas and New York.
Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial
NCT05685225
Recruiting
* This two-stage clinical trial will assess a novel combination therapy for acute migraine. In Stage 1 (factorial), participants will receive the combination, each individual component, or placebo. In Stage 2 (dose-finding), they will test three doses of the combination. Before both stages, participants will complete a run-in period, documenting a migraine attack without study medication. They will then treat one migraine attack in each stage. * 4 visits * Requirements: Migraine Diagnosis. BMI b... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/20/2025
Locations: Keystone Clinical Research, North Miami, Florida
Conditions: Migraine
Register for Updates
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
03/20/2025
Locations: Paradigm Clinical Research Center Inc, San Diego, California +119 locations
Conditions: Migraine
Register for Updates
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928
Recruiting
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/19/2025
Locations: Accel Research Sites Network - Neurology and Neurodiagnostic of Alabama, Hoover, Alabama +107 locations
Conditions: Migraine
Register for Updates
BE WELL With Migraine: Brain Education and WELLness With Migraine
NCT05987592
Recruiting
The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all their medications during this study. Information from this study may help determine how to better treat migraine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Cambridge Health Alliance - Center for Mindfulness and Compassion, Cambridge, Massachusetts +2 locations
Conditions: Migraine
Register for Updates
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
03/18/2025
Locations: Rehabilitation & Neurological Services /ID# 229969, Huntsville, Alabama +109 locations
Conditions: Migraine
Register for Updates
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
NCT05046613
Recruiting
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Gender:
FEMALE
Ages:
0 years and above
Trial Updated:
03/11/2025
Locations: PPD, Morrisville, North Carolina
Conditions: Migraine
Register for Updates
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
NCT05198245
Recruiting
The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.
Gender:
FEMALE
Ages:
Between 16 years and 49 years
Trial Updated:
03/11/2025
Locations: Research Triangle Institute d/b/a RTI Health Solutions, Research Triangle Park, North Carolina
Conditions: Migraine
Register for Updates
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06417775
Recruiting
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant i... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Central Research Associates /ID# 260161, Birmingham, Alabama +85 locations
Conditions: Migraine
Register for Updates
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914
Recruiting
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 1000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study across the world. Partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Neurology and Neurodiagnostics of Alabama /ID# 267614, Hoover, Alabama +35 locations
Conditions: Migraine
Register for Updates
Family Study of Affective and Anxiety Spectrum Disorders
NCT00071786
Recruiting
This study will examine how depression, anxiety, and migraine run in families. It will help in defining the risk factors for physical, mental, and health problems-as well as define ways that those problems may be prevented and treated. A broad range of ages among family members will be included to evaluate the patterns of how these disorders are expressed throughout people's lives. Children of all ages will be included, and those ages 8 to 17 will be interviewed directly. Assessments will be c... Read More
Gender:
ALL
Ages:
Between 7 years and 120 years
Trial Updated:
03/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mood Disorders, Sleep Disorders, Migraine
Register for Updates
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/24/2025
Locations: Central Research Associates, Birmingham, Alabama +174 locations
Conditions: Migraine
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/24/2025
Locations: Central Research Associates, Birmingham, Alabama +173 locations
Conditions: Migraine
Register for Updates